KLP Kapitalforvaltning AS Buys New Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

KLP Kapitalforvaltning AS acquired a new position in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) during the fourth quarter, according to the company in its most recent filing with the SEC. The fund acquired 16,823 shares of the medical equipment provider's stock, valued at approximately $1,505,000.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Raymond James Financial Inc. purchased a new stake in shares of Lantheus during the fourth quarter worth about $36,183,000. Groupama Asset Managment purchased a new stake in Lantheus during the 3rd quarter worth approximately $439,000. Swedbank AB raised its position in shares of Lantheus by 53.3% in the 4th quarter. Swedbank AB now owns 1,107,243 shares of the medical equipment provider's stock valued at $99,054,000 after purchasing an additional 385,000 shares in the last quarter. Keybank National Association OH purchased a new position in shares of Lantheus during the 4th quarter valued at approximately $27,526,000. Finally, Janus Henderson Group PLC grew its position in shares of Lantheus by 7.7% during the third quarter. Janus Henderson Group PLC now owns 3,588,571 shares of the medical equipment provider's stock worth $393,844,000 after buying an additional 257,022 shares in the last quarter. Institutional investors and hedge funds own 99.06% of the company's stock.

Lantheus Stock Performance

Shares of NASDAQ LNTH traded down $0.51 during midday trading on Wednesday, hitting $97.42. The company's stock had a trading volume of 550,674 shares, compared to its average volume of 941,171. Lantheus Holdings, Inc. has a 1-year low of $58.46 and a 1-year high of $126.89. The firm's fifty day moving average price is $93.45 and its 200-day moving average price is $96.29. The firm has a market cap of $6.67 billion, a P/E ratio of 16.21 and a beta of 0.38.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 EPS for the quarter, missing analysts' consensus estimates of $1.57 by ($0.23). The company had revenue of $391.11 million during the quarter, compared to analyst estimates of $376.61 million. Lantheus had a net margin of 28.57% and a return on equity of 44.29%. As a group, research analysts predict that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Lantheus news, CFO Robert J. Jr. Marshall sold 10,000 shares of the business's stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the completion of the transaction, the chief financial officer now directly owns 113,860 shares of the company's stock, valued at $11,445,207.20. The trade was a 8.07 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director James H. Thrall sold 1,000 shares of the firm's stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total transaction of $94,760.00. Following the completion of the sale, the director now owns 33,207 shares in the company, valued at $3,146,695.32. The trade was a 2.92 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 64,109 shares of company stock worth $6,110,806 in the last three months. 2.00% of the stock is owned by insiders.

Analysts Set New Price Targets

Several analysts recently issued reports on the stock. Truist Financial upped their price target on shares of Lantheus from $120.00 to $127.00 and gave the company a "buy" rating in a report on Thursday, February 27th. JMP Securities restated a "market outperform" rating and issued a $112.00 target price on shares of Lantheus in a research note on Tuesday, January 14th. The Goldman Sachs Group assumed coverage on shares of Lantheus in a research report on Wednesday, December 18th. They set a "buy" rating and a $143.00 price target on the stock. Finally, B. Riley lowered their price objective on Lantheus from $127.00 to $122.00 and set a "buy" rating for the company in a report on Friday, March 21st. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $129.43.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.